Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes tardive dyskinesia: no clinically important improvement compared with placebo (very low certainty).
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not measured · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes tardive dyskinesia: deterioration in symptoms compared with placebo (very low certainty).
1 finding from 1 review
Adverse effect: any adverse event · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: no clinically significant extrapyramidal adverse effects · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes acceptability of the treatment (measured by participants leaving the… compared with placebo (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes tardive dyskinesia: no clinically important improvement compared with phenobarbital (as active placebo) (very low certainty).
1 finding from 1 review
Tardive dyskinesia: deterioration in symptoms ‐ not measured · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: any · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes adverse events: any compared with phenobarbital (as active placebo) (very low certainty).
1 finding from 1 review
Tranquillisation or asleep: sedation ‐ medium termNumber of participants sedated · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes tranquillisation or asleep: sedation ‐ medium termNumber of… compared with placebo (very low certainty).
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes global state: no improvement ‐ medium termAs defined in each study compared with placebo (very low certainty).
1 finding from 1 review
Global impression ‐ need for additional medication ‐ medium term Number of participants requiring additional medication · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes global state: need for additional medication ‐ medium termNumber of… compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes adverse effects/events: extrapyramidal symptoms ‐ medium termNumber… compared with placebo (very low certainty).
1 finding from 1 review
Satisfaction with treatment: from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage · psychosis‐induced aggression or agitation
1 finding from 1 review
Economic outcomes: cost‐effectiveness ‐ clinically important · psychosis‐induced aggression or agitation
1 finding from 1 review
No clinically important response to treatment ‐ short term · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes no clinically important response to treatment ‐ short term compared with PLACEBO (very low certainty).
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty).
1 finding from 1 review